Molecular biopathology section

This section performs molecular assays (sequencing of more than 350 targets, PCR, qPCR, NGS etc.) in the context of clinical trials or research studies. This section is also involved in testing for mutations in the context of the Gustave Roussy Personalised Medicine programme.

The skill base of the section has been broadened by developing a team to research knowledge transfer in Haematology.
The nature of blood diseases has led to the development of methods of cell selection designed to isolate sub-populations from tumour samples.

Team members

• Guido Kroemer, Head of the platform
• Sylvère Durand, Analytics manager
• Fanny Aprahamian, Technical assistant

Metabolomics platform ressources

The facility consists of two complementary chromatography/mass spectrometry systems as well as Mass Spectrometry Imaging:

• UHPLC U3000 Dionex - Orbitrap q-Exactive Thermo Scientific
• UHPLC 1290 Binary Pump Agilent - QQQ 6470 Agilent
• DESI-SYNAPT XS Waters

We also have a complete dedicated sample preparation room, equipped with -80°C freezer.

Metabolomics platform activities

Mass-spectrometry is the core technology of our facility enabling to measure all potential classes of metabolites for both exploratory and targeted approaches.

Exploratory metabolomics profiling is performed on a high resolution mass spectrometer (HRMS) coupled to ultra-high performance liquid chromatography (UHPLC).

Targeted metabolomics relies on multiple reaction monitoring (MRM) after separation by UHPLC, depending on the properties of the metabolites of interest.

Team members

• Head of the genomic platform: Nathalie DROIN, PhD
  (nathalie.droin@gustaveroussy.fr)
• Marie BRECKLER, Technician
• Betty LEITE, Technician
• Audrey NAIMO, Technician
• Maëla FRANCILLETTE, engineer
• Béatrice FIET, assistant manager

Collective email address: GD-UGF@gustaveroussy.fr

Equipment

• 2 Bioanalyzer 2100 (Agilent)
• 1 FragmentAnalyzer (Agilent)
• 1 S220 Ultrasonicator (Covaris)
• 1 E220 Ultrasonicator (Covaris)

• 1 Robot Bravo (Agilent)
• 1 Robot SpriWorks (Beckman)

• 2 Chromium™ Controller (10X Genomics)
• 1 Tapestri (Mission Bio)

1 NovaSeq6000 (Illumina)

• 1 MiSeq (Illumina)
• 1 MiniSeq (Illumina)
• 1 PromethION 48 (Oxford Nanopore)

Gustave Roussy's US AMMICa Genomics Platform (INSERM US23 / CNRS UMS3655) aims to characterize cancers and experimental models using innovative genomic approaches.

Imaging and Cytometry Platform

• Cytometry & Mass imaging
• Microscopy
• Clinical Transfer Imaging

Gustave Roussy Transfert team members​

• CEO
  Fabrice Barlesi
• Executive director
  Christophe Javaud 
• Business developers
  Jérôme Gaborit
  Pierre Gandille
• Patent engineer / Responsable propriété intellectuelle
  Frédérique Le Bellego
• Patent engineer
  Sacha Cataldo
• Chargée de mission Accords et licences / Responsable gestion financière
  Daphné Descarpentries

From Innovation to the Patient

In 2000, Gustave Roussy established its subsidiary devoted to development: Gustave Roussy Transfert.
The Institute is the majority shareholder in this limited liability company with a capital of 200,200 euros, which is intended to :